- BriaCell Therapeutics Corp. (BCT) has announced a research collaboration with Harvard Medical School in support of a project led by Joan S. Brugge
- The project aims to discover new targets that may lead to the development of novel anti-cancer treatments
- The research will focus on the discovery and development of novel targets to enhance tumour cell responsiveness to chemotherapy and immunotherapies in specific cancers
- BriaCell will have the option to negotiate a licence to innovations owned by Harvard University that arise under the one-year collaboration
- BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer
- BriaCell Therapeutics Corp. was up 0.87 per cent, trading at $8.12 at 10:21 AM ET
BriaCell Therapeutics (BCT) has announced a research collaboration with Harvard Medical School, supporting a project led by Joan S. Brugge, Ph.D.
The aim of the project is to discover new targets that may lead to the development of novel anti-cancer treatments.
The focus of the research collaboration will be on discovering and developing novel targets to enhance tumour cell responsiveness to chemotherapy and immunotherapies in specific cancers, including lung, head and neck, cervical, and bladder cancers.
Joan S. Brugge, the Louise Foote Pfeiffer Professor of Cell Biology and Co-Director of the Ludwig Cancer Centre, will lead the research team at Harvard Medical School.
“We are grateful for the opportunity to work with Prof. Brugge and her expert team at Harvard Medical School to advance discovery in oncology,” noted Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer.
“We are hopeful that insights from this effort may potentially inform BriaCell’s future R&D aims in developing novel anti-cancer drugs,” he added.
“Scientists have made tremendous strides in understanding the basic biology of cancer over the last decade,” said Joan Brugge.
“Despite this formidable progress, persistent challenges remain in translating these discoveries into effective and safe precision-targeted cancer treatments, and our work aims to solve these challenges,” she added.
BriaCell will have the option to negotiate a licence for innovations owned by Harvard University that arise under the one-year collaboration. Harvard’s Office of Technology Development coordinated the research agreement.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
BriaCell Therapeutics Corp. was up 0.87 per cent, trading at $8.12 at 10:21 AM ET.
